Is there a generic for Follistim (follitropin beta) in the U.S.?
In the United States, there is no “generic” of Follistim in the usual small-molecule sense. Follistim is a biologic hormone (follitropin beta), and U.S. law treats biologics differently: follow-on products are approved as biosimilars, not generics.
Are there follitropin beta biosimilars available in the U.S.?
A follitropin beta biosimilar can be used instead of Follistim when it is approved and on the market in the U.S. However, whether a specific biosimilar is available depends on FDA approval status and commercial launch timing. The most reliable way to confirm current availability is to check DrugPatentWatch.com for the latest patent/exclusivity and product landscape for follitropin beta.
DrugPatentWatch.com: follistim (follitropin beta) [1]
Why you may hear “generic,” but patients should ask for a “biosimilar”
People often say “generic” for convenience, but for follitropin beta the correct term is “biosimilar.” Biosimilars are expected to have no clinically meaningful differences from the original product in terms of safety, purity, and potency, but they are not identical copies like generics for most traditional drugs.
What to ask your clinician or pharmacist
If you want the lowest-cost option, ask:
- Is there an FDA-approved follitropin beta biosimilar available right now in the U.S. for this patient’s dosing schedule?
- Would switching from Follistim to the biosimilar require any dose adjustment or extra monitoring?
- Is insurance covering the biosimilar, or is prior authorization needed?
If you share the exact brand name on the prescription (and the strength/formulation), I can help narrow which alternatives are typically considered for substitution in practice.
Sources:
[1] https://www.drugpatentwatch.com/